Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
28 09 2019
Historique:
received: 25 10 2018
revised: 14 02 2019
accepted: 14 02 2019
pubmed: 30 6 2019
medline: 23 10 2019
entrez: 29 6 2019
Statut: ppublish

Résumé

Public health is a priority for the Chinese Government. Evidence-based decision making for health at the province level in China, which is home to a fifth of the global population, is of paramount importance. This analysis uses data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to help inform decision making and monitor progress on health at the province level. We used the methods in GBD 2017 to analyse health patterns in the 34 province-level administrative units in China from 1990 to 2017. We estimated all-cause and cause-specific mortality, years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), summary exposure values (SEVs), and attributable risk. We compared the observed results with expected values estimated based on the Socio-demographic Index (SDI). Stroke and ischaemic heart disease were the leading causes of death and DALYs at the national level in China in 2017. Age-standardised DALYs per 100 000 population decreased by 33·1% (95% uncertainty interval [UI] 29·8 to 37·4) for stroke and increased by 4·6% (-3·3 to 10·7) for ischaemic heart disease from 1990 to 2017. Age-standardised stroke, ischaemic heart disease, lung cancer, chronic obstructive pulmonary disease, and liver cancer were the five leading causes of YLLs in 2017. Musculoskeletal disorders, mental health disorders, and sense organ diseases were the three leading causes of YLDs in 2017, and high systolic blood pressure, smoking, high-sodium diet, and ambient particulate matter pollution were among the leading four risk factors contributing to deaths and DALYs. All provinces had higher than expected DALYs per 100 000 population for liver cancer, with the observed to expected ratio ranging from 2·04 to 6·88. The all-cause age-standardised DALYs per 100 000 population were lower than expected in all provinces in 2017, and among the top 20 level 3 causes were lower than expected for ischaemic heart disease, Alzheimer's disease, headache disorder, and low back pain. The largest percentage change at the national level in age-standardised SEVs among the top ten leading risk factors was in high body-mass index (185%, 95% UI 113·1 to 247·7]), followed by ambient particulate matter pollution (88·5%, 66·4 to 116·4). China has made substantial progress in reducing the burden of many diseases and disabilities. Strategies targeting chronic diseases, particularly in the elderly, should be prioritised in the expanding Chinese health-care system. China National Key Research and Development Program and Bill & Melinda Gates Foundation.

Sections du résumé

BACKGROUND
Public health is a priority for the Chinese Government. Evidence-based decision making for health at the province level in China, which is home to a fifth of the global population, is of paramount importance. This analysis uses data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to help inform decision making and monitor progress on health at the province level.
METHODS
We used the methods in GBD 2017 to analyse health patterns in the 34 province-level administrative units in China from 1990 to 2017. We estimated all-cause and cause-specific mortality, years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), summary exposure values (SEVs), and attributable risk. We compared the observed results with expected values estimated based on the Socio-demographic Index (SDI).
FINDINGS
Stroke and ischaemic heart disease were the leading causes of death and DALYs at the national level in China in 2017. Age-standardised DALYs per 100 000 population decreased by 33·1% (95% uncertainty interval [UI] 29·8 to 37·4) for stroke and increased by 4·6% (-3·3 to 10·7) for ischaemic heart disease from 1990 to 2017. Age-standardised stroke, ischaemic heart disease, lung cancer, chronic obstructive pulmonary disease, and liver cancer were the five leading causes of YLLs in 2017. Musculoskeletal disorders, mental health disorders, and sense organ diseases were the three leading causes of YLDs in 2017, and high systolic blood pressure, smoking, high-sodium diet, and ambient particulate matter pollution were among the leading four risk factors contributing to deaths and DALYs. All provinces had higher than expected DALYs per 100 000 population for liver cancer, with the observed to expected ratio ranging from 2·04 to 6·88. The all-cause age-standardised DALYs per 100 000 population were lower than expected in all provinces in 2017, and among the top 20 level 3 causes were lower than expected for ischaemic heart disease, Alzheimer's disease, headache disorder, and low back pain. The largest percentage change at the national level in age-standardised SEVs among the top ten leading risk factors was in high body-mass index (185%, 95% UI 113·1 to 247·7]), followed by ambient particulate matter pollution (88·5%, 66·4 to 116·4).
INTERPRETATION
China has made substantial progress in reducing the burden of many diseases and disabilities. Strategies targeting chronic diseases, particularly in the elderly, should be prioritised in the expanding Chinese health-care system.
FUNDING
China National Key Research and Development Program and Bill & Melinda Gates Foundation.

Identifiants

pubmed: 31248666
pii: S0140-6736(19)30427-1
doi: 10.1016/S0140-6736(19)30427-1
pmc: PMC6891889
pii:
doi:

Substances chimiques

Particulate Matter 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1145-1158

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Lancet. 2013 Jun 8;381(9882):1987-2015
pubmed: 23746901
Lancet. 2018 Nov 10;392(10159):1684-1735
pubmed: 30496102
Value Health Reg Issues. 2017 May;12:112-114
pubmed: 28648308
Semin Cancer Biol. 2011 Feb;21(1):59-69
pubmed: 21144900
J Am Stat Assoc. 2013 Mar;108(501):96-110
pubmed: 23579202
Soc Psychiatry Psychiatr Epidemiol. 2005 Oct;40(10):792-8
pubmed: 16205852
Obes Rev. 2014 Jan;15 Suppl 1:8-15
pubmed: 24341754
BMC Public Health. 2014 Feb 05;14:121
pubmed: 24499429
Lancet. 2008 Oct 25;372(9648):1493-501
pubmed: 18930531
Lancet. 2018 Nov 10;392(10159):2091-2138
pubmed: 30496107
J R Stat Soc Ser A Stat Soc. 2015 Oct;178(4):977-1007
pubmed: 26612972
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Lancet. 2002 Mar 9;359(9309):835-40
pubmed: 11897283
Emerg Infect Dis. 2017 May;23(5):765-772
pubmed: 28418296
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
Lancet. 2016 Jan 16;387(10015):273-83
pubmed: 26510780
J Health Popul Nutr. 2018 Apr 12;37(1):8
pubmed: 29650054
Lancet. 2019 Jan 19;393(10168):241-252
pubmed: 30554785
Recent Results Cancer Res. 2011;188:75-84
pubmed: 21253790
Lancet. 2012 Mar 3;379(9818):843-52
pubmed: 22386037
Lancet. 2016 Oct 8;388(10053):1775-1812
pubmed: 27733286
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Chest. 2016 Dec;150(6):1269-1280
pubmed: 27693597
Lancet. 2010 Sep 18;376(9745):959-74
pubmed: 20851260
Reprod Health Matters. 2014 Nov;22(44):164-73
pubmed: 25555773
Lancet. 2016 Jan 16;387(10015):251-72
pubmed: 26510778
Lancet. 2012 Dec 15;380(9859):2063-6
pubmed: 23245602
J Hazard Mater. 2011 Feb 28;186(2-3):1594-600
pubmed: 21194838
Am J Public Health. 2016 Dec;106(12):2113-2125
pubmed: 27736219
Popul Stud (Camb). 2016;70(1):21-37
pubmed: 26902913
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Lancet. 2018 Nov 10;392(10159):1995-2051
pubmed: 30496106
Lancet. 2016 Oct 8;388(10053):1725-1774
pubmed: 27733285
BMJ Open. 2017 Apr 11;7(4):e014914
pubmed: 28404613
Vaccine. 2009 Nov 5;27(47):6550-7
pubmed: 19729084
PLoS Med. 2016 Aug 9;13(8):e1002116
pubmed: 27504831
Prev Chronic Dis. 2014 May 22;11:E88
pubmed: 24854239

Auteurs

Maigeng Zhou (M)

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Haidong Wang (H)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Xinying Zeng (X)

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Peng Yin (P)

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Jun Zhu (J)

National Office for Maternal and Child Health Surveillance, Chengdu, China.

Wanqing Chen (W)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

Xiaohong Li (X)

National Office for Maternal and Child Health Surveillance, Chengdu, China.

Lijun Wang (L)

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Limin Wang (L)

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Yunning Liu (Y)

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Jiangmei Liu (J)

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Mei Zhang (M)

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Jinlei Qi (J)

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Shicheng Yu (S)

Chinese Center for Disease Control and Prevention, Beijing, China.

Ashkan Afshin (A)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Emmanuela Gakidou (E)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Scott Glenn (S)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Varsha Sarah Krish (VS)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Molly Katherine Miller-Petrie (MK)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

W Cliff Mountjoy-Venning (WC)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Erin C Mullany (EC)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Sofia Boston Redford (SB)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Hongyan Liu (H)

China Population and Development Research Center, Beijing, China.

Mohsen Naghavi (M)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Simon I Hay (SI)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Linhong Wang (L)

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Christopher J L Murray (CJL)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. Electronic address: cjlm@uw.edu.

Xiaofeng Liang (X)

Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: liangxf@chinacdc.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH